The company operates in the veterinary biotechnology sector, focusing on developing innovative biological drugs based on mesenchymal stem cells. Main projects include drug candidates for treating osteoarthritis in dogs (BCX-CM-J), atopic dermatitis in dogs (BCX-CM-AD), and lameness in horses (BCX-EM). The firm has developed its proprietary ALLO-BCLX technology, enabling allogeneic application of stem cells. The company owns a certified pharmaceutical manufacturing facility and conducts clinical trials of its products. In May 2024, an application was submitted to the European Medicines Agency for marketing authorization of the BCX-CM-J product.